Early failure of dental implants and TNF-α (G-308A) gene polymorphism

Implant Dentistry

Volumn 13, Issue 1, 2004, Pages 95-101

  Campos, Maria Isabela Guimarães ^a   Dos Santos, Maria Cristina Leme Godoy ^a   Trevilatto, Paula Cristina ^b   Scarel Caminaga, Raquel Mantuaneli ^c   Bezerra, Fábio José Barbosa ^d   Line, Sergio Roberto Peres ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^c UNIVERSIDADE DO SAGRADO CORAÇÃO   (Brazil)

^d Departamento de Morfologia ^*

Author keywords

Dental implants; Implant failure; Osseointegration; Polymorphism; TNF alpha

Indexed keywords

GENOMIC DNA; TUMOR NECROSIS FACTOR ALPHA; ADENINE; DNA; GUANINE;

ADULT; ARTICLE; BRAZIL; CHEEK MUCOSA; CHI SQUARE TEST; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC RISK; GENOTYPE; HUMAN; HUMAN CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; TOOTH IMPLANTATION; TREATMENT FAILURE; ALLELE; CHI SQUARE DISTRIBUTION; DENTAL SURGERY; FEMALE; GENETICS; MALE; MIDDLE AGED;

ADENINE; ADULT; ALLELES; CHI-SQUARE DISTRIBUTION; DENTAL RESTORATION FAILURE; DNA; FEMALE; GENOTYPE; GUANINE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2342577561     PISSN: 10566163     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ID.0000116458.60585.C4     Document Type: Article

References (56)

1. Adell R, Eriksson B, Lekholm U, et al. Long-term follow-up study of osseointegrated implants in the treatment of totally edentulous jaws. Int J Oral Maxillofac Implants. 1990;5:347-359.
2. Lekholm UGJ, Henry P, Higuchi K, et al. Survival of the Branemark implant in partially edentulous jaws: A 0-10 year prospective multicenter study. Int J Oral Maxillofac Implants. 1999;14:636-645.
3. Esposito M, Hirsch JM, Lekholm U, et al. Biological factors contributing to failures of osseointegrated oral implants. (I). Success criteria and epidemiology. Eur J Oral Sci. 1998;106:527-551.
4. El Askary AS, Meffert RM, Griffin T. Why do dental implants fail? Part I. Implant Dentistry. 1999;8:173-185.
5. Parfitt AM. The two faces of growth: Benefits and risks to bone integrity. Osteoporos Int. 1994;4:382-398.
6. Horowitz MC, Lorenzo JA. Local Regulators of Bone, 1st ed. New York: Academic Press; 1996:687-700.
7. Beutler B, Cerami A. The biology of cachectin/TNF - A primary mediator of the host response. Annu Rev Immunol. 1989;7:625-655.
8. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992;10:411-452.
9. Manogue KR, Van Deventer SJH, Cerami A. Tumor Necrosis Factor or Cachectin, 1st ed. New York: Academic Press; 1991:241-256.
10. Meikle MC, Atkinson SJ, Ward RV, et al. Gingival fibroblasts degrade type I collagen films when stimulated with tumor necrosis factor and interleukin 1: Evidence that breakdown is mediated by metalloproteinases. J Periodontal Res. 1989;24:207-213.
11. Elias JA, Gustilo K, Baeder W, et al. Synergistic stimulation of fibroblast prostaglandin production by recombinant interleukin 1 and tumor necrosis factor. J Immunol. 1987;138:3812-3816.
12. Chaudhary LR, Spelsberg TC, Riggs BL. Production of various cytokines by normal human osteoblast-like cells in response to interleukin-1 beta and tumor necrosis factor-alpha: Lack of regulation by 17 beta-estradiol. Endocrinology. 1992;130:2528-2534.
13. Bertolini DR, Nedwin GE, Bringman TS, et al. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature. 1986;319:516-518.
14. Van Der Pluijm G, Most W, Van Der Wee-Pals L, et al. Two distinct effects of recombinant human tumor necrosis factor-alpha on osteoclast development and subsequent resorption of mineralized matrix. Endocrinology. 1991;129:1596-1604.
15. Johnson RA, Boyce BF, Mundy GR, et al. Tumors producing human tumor necrosis factor induced hypercalcemia and osteoclastic bone resorption in nude mice. Endocrinology. 1989;124:1424-1427.
16. Feldman M. TNF-α: A pivotal role in rheumatoid arthritis. Br J Rheumatol. 1992;6:485-516.
17. Jacob CO, Fronek Z, Lewis GD. Heritable major histocompatibility complex class Lis associated differences in production of tumor necrosis factor-α relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci U S A. 1990;87:1233-1237.
18. Zinman B, Hanley AJG, Harris SB. Circulating tumor necrosis factor-α concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab. 1999;84:272-278.
19. Galbraith GM, Steed RB, Sanders JJ, et al. Tumor necrosis factor alpha production by oral leukocytes: Influence of tumor necrosis factor genotype. J Periodontol. 1998:69:428-433.
20. Stashenko P, Jandinski JJ, Fujiyoshi P, et al. Tissue levels of bone resorptive cytokines in periodontal disease. J Periodontol. 1991:62:504-509.
21. Rossomando EF, Kennedy JE, Hadjimichael J, et al. Tumor necrosis factor alpha in gingival crevicular fluid as a possible indicator of periodontal disease in humans. Arch Oral Biol. 1990;35:431-434.
22. Wilson AG, Di Giovine FS, Blakemore AI, et al. Single base polymorphism in the human tumor necrosis factor alpha (TNF alpha) gene detectable by Ncol restriction of PCR product. Hum Mol Genet. 1992;1:353.
23. Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol. 1997;34:391-399.
24. Wilson AG, Symons JA, McDowell TL, et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997;94:3195-3199.
25. Brinkman BM, Zuijdeest D, Kaijzel EL, et al. Relevance of the tumor necrosis factor alpha (TNF alpha) -308 promoter polymorphism in TNF alpha gene regulation. J Inflamm. 1995-96;46:32-41.
26. Perry RT, Collins JS, Wiener H, et al. The role of TNF and its receptors in Alzheimer's disease. Neurobiol Aging. 2001;22:873-883.
27. Danis VA, Millington M, Hyland V, et al. Increased frequency of the uncommon allele of a tumor necrosis factor alpha polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis Markers. 1995:12:127-133.
28. Rood MJ, Van Krugten MV, Zanelli E, et al. TNF -308 and HLA-DR3 alleles contribute independently to susceptibility to systemic lupus erythematosus. Arthritis Rheum. 2000;43:129-134.
29. Witte JS, Palmer LJ, O'Connor RD, et al. Relation between tumor necrosis factor polymorphism TNFalpha -308 and risk of asthma. Eur J Hum Genet. 2002;10:82-85.
30. Heijmans BT, Westendorp RG, Droog S, et al. Association of the tumor necrosis factor alpha -308G/A polymorphism with the risk of diabetes in an elderly population-based cohort. Genes Immun. 2002;3:225-228.
31. Kao RT, Curtis DA, Richards DW, et al. Increased interleukin-1 beta in the crevicular fluid of diseased implants. Int J Oral Maxillofac Implants. 1995;10:696-701.
32. Panagakos FS, Aboyoussef H, Dondero R, et al. Detection and measurement of inflammatory cytokines in implant crevicular fluid: A pilot study, Int J Oral Maxillofac Implants. 1996;11:794-799.
33. Salcetti JM, Moriarty JD, Cooper LF, et al. The clinical, microbial, and host response characteristics of the failing implant. Int J Oral Maxillofac Implants. 1997;12:32-42.
34. Schwartz Z, Lohmann CH, Cochran DL, et al. Bone Regulating Mechanisms on Implant Surfaces, 1st ed. Chicago: Quintessence Publishing; 1999:41-54.
35. Van Der Linden MW, Huizinga TW, Stoeken DJ, et al. Determination of tumor necrosis factor-alpha and interleukin-10 production in a whole blood stimulation system: Assessment of laboratory error and individual variation. J Immunol Methods. 1998:218:63-71.
36. Westendorp RG, Langermans JA, Huizinga TW, et al. A genetic influence on cytokine production in meningococcal disease. Lancet. 1997;349:1912-1913.
37. Trevilatto PC, Line SRP. Use of buccal epithelial cells for PCR amplification of large DNA fragments. J Forensic Odontostomatol. 2000;18:6-9.
38. Maniatis T, Fritsch EF, Sambrook J. Molecular Cloning: A Laboratory Manual, 2nd ed. New York: Cold Spring Harbor Laboratory Press; 1989:458-463.
39. Sanguinetti CJ, Dias EM, Simpson AJG. Rapid silver staining and recovery of PCR products separated on polyacrylamide gels. Biotechniques. 1994;17:915-919.
40. Esposito M, Hirsch JM, Lekholm U, et al. Biological factors contributing to failures of osseointegrated oral implants. (II). Etiopathogenesis. Eur J Oral Sci. 1998;106:721-764.
41. Santos MCLG, Campos MIG, Line SRP. Early dental implant failure: A review of literature. Braz J Oral Sci. 2002;1:103-111.
42. El Askary AS, Meffert RM, Griffin T. Why do dental implants fail? Part II. Implant Dentistry. 1999;8:265-277.
43. Deas DE, Mikotowicz JJ, Mackey SA, et al. Implant failure with spontaneous rapid exfoliation: Case reports. Implant Dentistry. 2002;11:235-242.
44. Weyant RJ, Burt BA. An assessment of survival rates and within-patient clustering of failures for endosseous oral implants. J Dent Res. 1993;72:2-8.
45. Hutton JE, Heath MR, Chai JY, et al. Factors related to success and failure rates at 3-year follow-up in a multicenter study of overdentures supported by Branemark implants. Int J Oral Maxillofac Implants. 1995;10:33-42.
46. Deem LP, Bassiouny MA, Deem TE. The sequential failure of osseointegrated submerged implants. Implant Dentistry. 2002;11:243-248.
47. Ekfeldt A, Christiansson U, Eriksson T, et al. A retrospective analysis of factors associated with multiple implant failures in maxillae. Clin Oral Implants Res. 2001;12:462-467.
48. Wilson TGJ, Nunn M. The relationship between the interleukin-1 periodontal genotype and implant loss. Initial data. J Periodontol. 1999;70:724-729.
49. Kornman KS, Crane A, Wang HY, et al. The interleukin-1 genotype as a severity factor in adult periodontal disease. J Clin Periodontol. 1997;24:72-77.
50. Rogers MA, Figliomeni L, Baluchova K, et al. Do interleukin-1 polymorphisms predict the development of periodontitis or the success of dental implants? J Periodontol. 2002;37:37-41.
51. Feloutzis A, Lang NP, Tonetti MS, et al. IL-1 gene polymorphism and smoking as risk factors for peri-implant bone loss in a well-maintained population. Clin Oral Implants Res. 2003;14:10-17.
52. Wilson AG, Vries N, Pociot F, et al. An allelic polymorphism within the human tumor necrosis factor α promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med. 1993;117:557-560.
53. Abraham LJ, French MAH, Dawkins RL. Polymorphic MHC ancestral haplotypes affect the activity of tumor necrosis factor-alpha. Clin Exp Immunol. 1993;92:14-18.
54. Perrey C, Pravica V, Sinnott PJ, et al. Genotyping for polymorphisms in interferon-gamma, interleukin-10, transforming growth factor-beta 1 and tumour necrosis factor-alpha genes: A technical report. Transpl Immunol. 1998;6:193-197.
55. Perala DG, Chapman RJ, Gelfand JA, et al. Relative production of IL-1 beta and TNF alpha by mononuclear cells after exposure to dental implants. J Periodontol. 1992;63:426-430.
56. Tsutsui T, Kawaguchi H, Fujino A, et al. Exposure of macrophage-like cells to titanium particles does not affect bone resorption, but inhibits bone formation. J Orthop Sci. 1999;4:32-38.